Barycela (varicella II vaccine) / GC Biopharma 
Welcome,         Profile    Billing    Logout  
 3 Diseases   2 Trials   2 Trials   11 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Barycela (varicella II vaccine) / GC Biopharma
NCT05422508: Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Recruiting
2
230
RoW
MG1111 (BARICELA), VARIVAX, Suduvax
Green Cross Corporation
Varicella
06/25
06/27
NCT05664152: An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

Not yet recruiting
N/A
250
NA
MG1111
GC Biopharma Corp
Varicella Zoster Virus Infection
04/23
06/23

Download Options